- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04309058
Observation of the Effect of Vitamin D Supplementation on Chronic Course of Patients With Ulcerative Colitis Based on Vitamin D Receptor Fok I Gene Polymorphism
Observation of the Effect of Vitamin D Supplementation on Chronic Course of Patients With Ulcerative Colitis Based on Vitamin D Receptor Fok I Gene Polymorphism,a Prospective Cohort Study
Aims:Prospectively observe the effects of Vitamin D drops supplementation on the chronic course of ulcerative colitis patients, analyze whether the effect of Vitamin D drops on UC patients is affected by factors such as disease site, disease activity, treatment, etc.Exploring the relationship between Fok I gene polymorphism and the efficacy of vitamin D supplementation. Provide a certain theoretical basis for "precision treatment" for UC patients in the future.
Design:It is a prospective cohort study. Investigators include a total of 100 participants with UC according to the inclusion and exclusion criteria, and divide them into two groups to assess their initial disease activity and detect related indicators. At the same time,investigators detect the Fok I gene polymorphism in all participants.One group is given Vitamin D drops 400IU per day orally, and the control group do not intervene. Participants' disease activity is assessed at baseline and related indicators are determined. The disease activity is re-evaluated in the 3rd, 6th, 9th, and 12th months, and the serum indexes are re-evaluated.Investigators use statistical methods to analyze whether Vitamin D drops supplementation treatment can increase the serum 25 (OH) D level of UC participants, improve the condition of UC participants,relationship with Fok I gene polymorphism,and analyze the effects of Vitamin D drops on participants with UC is affected by factors such as disease site, disease activity, and treatment.
Aperçu de l'étude
Statut
Intervention / Traitement
Description détaillée
- The research can be started only after approval by the Medical Ethics Committee of the Second Affiliated Hospital of Wenzhou Medical University.
- According to the "Consensus on Diagnosis and Treatment of Inflammatory Bowel Disease" formulated by the Beijing Conference in 2018 as a standard, patients with clear diagnosis of UC are collected.Other diagnostic criteria include Vitamin D deficiency (<= 20ng / ml). Exclusion criteria included pregnancy, breastfeeding, liver and kidney dysfunction, concurrent autoimmune diseases, and use of antiepileptic drugs or drugs metabolized by liver cytochrome P450 enzymes.
- Assess disease activity of UC participants based on the "Moya score".
- General information about participants with UC is collected.
- Detection of Fok I gene polymorphism using Snapshot technology.
- The level of serum 25 (OH) D of participants is detected.
- Serum C-reactive protein, erythrocyte sedimentation rate, albumin, calcium and phosphorus levels are measured.
- Develop a treatment plan for all participants.
- Participants are divided into two groups, one group is given oral Vitamin D drops 400IU/ d, and the other group do not intervene.
- The disease activity is re-evaluated in the 3rd, 6th, 9th, and 12th months, and the above serum indexes are re-evaluated.
Follow-up for 12 months. By comparing the above indicators, observe that in the Han population:
- Can Vitamin D drops supplementation increase serum 25 (OH) D levels in patients with UC?
- Can Vitamin D drops supplementation improve the condition of patients with UC?
- Whether Fok I gene polymorphism affect the efficacy of Vitamin D drops supplementation therapy?
- Whether the effects of Vitamin D drops on UC patients is affected by factors such as disease site, disease activity, treatment, etc ..
- Through statistical analysis, comprehensive analysis of the effectiveness and safety of Vitamin D drops supplementation in Han patients with UC, and its relationship with Fok I gene polymorphism, providing a theoretical basis for further "precise treatment" intervention in inflammatory bowel disease.
Type d'étude
Inscription (Anticipé)
Phase
- Première phase 1
Contacts et emplacements
Lieux d'étude
-
-
Zhejiang
-
Wenzhou, Zhejiang, Chine
- SAHWenzhouMU
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Enfant
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Clearly diagnosed patients with UC
- Vitamin D deficiency (<= 20ng / ml)
Exclusion Criteria:
- Pregnancy, lactation
- Liver and kidney insufficiency
- Co-morbid with other autoimmune diseases
- Use antiepileptic drugs or drugs metabolized by liver cytochrome P450 enzymes
- Vitamin D level is normal or high
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Non randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Aucune intervention: Contrôle
L'autre groupe n'intervient pas.
|
|
|
Expérimental: Gouttes de vitamine D
Ce groupe de patients va se supplémenter avec des gouttes de Vitamine D 400UI/j par voie orale.
|
Vitamin D-deficient UC patients are divided into two groups, one group is given orally with Vitamin D drops 400IU / d, while the other group do not interfere.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Genotype frequency of vitamin D receptor single nucleotide polymorphisms in participants
Délai: 1 year
|
Genotype frequency of vitamin D receptor single nucleotide polymorphisms in participants can reflect whether it is related to the severity of the disease and how much relevance.
|
1 year
|
|
Serum 25 (OH) D level
Délai: 1year
|
Because serum 25 (OH) D levels are relatively stable, they are considered the most reliable indicator of vitamin D status
|
1year
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Vitesse de sédimentation
Délai: 1 an
|
La RSE peut être utilisée pour refléter le degré d'inflammation dans le corps.
|
1 an
|
|
Blood calcium and phosphorus
Délai: 1year
|
Monitoring serum calcium and phosphorus levels to prevent toxic side effects.
|
1year
|
|
Concentration of C-reactive protein in participants
Délai: 1year
|
Concentration of C-reactive protein can be used to reflect the degree of inflammation in the human body.
|
1year
|
Collaborateurs et enquêteurs
Les enquêteurs
- Chercheur principal: Jiang yi, PhD, Second Affiliated Hospital of Wenzhou Medical University
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Anticipé)
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies du système digestif
- Processus pathologiques
- Maladies gastro-intestinales
- Troubles nutritionnels
- Gastro-entérite
- Maladies du côlon
- Maladies intestinales
- Avitaminose
- Maladies de carence
- Malnutrition
- Maladies intestinales inflammatoires
- Ulcère
- Carence en vitamine D
- Colite
- Colite ulcéreuse
- Effets physiologiques des médicaments
- Micronutriments
- Vitamines
- Agents de conservation de la densité osseuse
- Vitamine D
Autres numéros d'identification d'étude
- SAHoWMU-CR2017-01-121
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .